Tag: Business

Categories
Healthcare Science

Legend Biotech begins phase 1 clinical trial in the U.S. to evaluate investigational anti-CD4 CAR-T therapy for relapsed or refractory T-Cell lymphoma

SOMERSET, N.J. — (BUSINESS WIRE) — $LEGN–Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, has announced the start of a Phase 1 clinical trial in the United States for LB1901, an investigational autologous CD4-targeted chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). LB1901 targets CD4, a surface membrane glycoprotein uniformly expressed in most TCL subtypes. The trial follows the U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application submitted by Legend Biotech.

The Phase 1 trial is being led by Dr. Swaminathan P. Iyer, Professor of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, and is an open label, multi-center and multicohort clinical study in patients with relapsed or refractory PTCL or CTCL (NCT04712864). Recruitment in the trial has begun in the U.S.

“We are excited by the promise of LB1901, and we look forward to further evaluating the safety and tolerability of LB1901. Determining the optimal dose for subsequent evaluation is one of the key objectives of this trial,” said Dr. Lida Pacaud, Vice President of Clinical Development at Legend Biotech. “The number of patients who relapse or are refractory to current TCL treatments is significant, and this trial will provide important information about the potential of CAR-T therapy to treat this disease.”

T-cell lymphoma is a heterogeneous group of lymphoid malignancies that account for less than 15 percent of non-Hodgkin’s lymphoma cases in the US.i,ii PTCL comprises subtypes that are uncommon and often aggressive, with a 5-year overall survival of only 39%.iii,iv CTCL are a group of T-cell malignancies that occur primarily in the skin.v Despite current treatment options, a substantial proportion of patients with PTCL or CTCL experiences relapse. A high unmet medical need remains for patients with relapsed or refractory PTCL and CTCL.

About the Clinical Development Program

LB1901-TCL-001 (NCT04712864) is a Phase 1 open-label, multicenter study of LB1901 in patients with histologically confirmed CD4+ RR PTCL (PTCL not otherwise specified, or PTCL-NOS, and angioimmunoblastic T cell lymphoma, or AITL) or RR CTCL (mycosis fungoides and Sézary syndrome). The primary objectives are to characterize the safety and tolerability of LB1901 and determine the optimal dose.

About Legend Biotech

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 900 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture best-in-class cell therapies for patients in need. We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, cilta-cel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being studied in registrational clinical trials.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives; the anticipated timing of, and ability to progress, the Phase 1 clinical trial of LB1901 in RR PTCL and RR CTCL; patient enrollment in the LB1901 Phase 1 clinical trial; and the potential benefits of LB1901 or any of our other product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 2, 2021. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation as anticipated, believed, estimated or expected. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

i Scherer LD, Brenner MK, Mamonkln M. Chimeric antigen receptors for T-cell malignancies. Frontiers in Oncology. 2019 March;9(article 126):1-10.

ii American Cancer Society. Types of T-cell Lymphoma. Available at: https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/t-cell-lymphoma.html. Accessed August 2021.

iii Casulo C, O’Connor O, Shustov A, Fanale M, Friedberg JW, Leonard JP, et al. T-cell lymphoma: Recent advances in characterization and new opportunities for treatment. J Natl Cancer Inst. 2017;109(2):1-9.

iv Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011;2011:623924.

v Scarfo I, Frigault M, Maus M. CAR-based approaches to cutaneous T-cell lymphoma. Frontiers in Oncology. 2019;9(article 259):1-6.

Contacts

Investor Contacts:
Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech

jessie.yeung@legendbiotech.com or investor@legendbiotech.com

Crystal Chen, Manager of Investor Relations and Corporate Communications, Legend Biotech

crystal.chen@legendbiotech.com

Press Contact:
Tina Carter, Corporate Communications Lead, Legend Biotech

tina.carter@legendbiotech.com
(908) 331-5025

Categories
Business Technology

Dodge Data & Analytics launches suite of microsites for construction professionals

Targeted Industry Newsfeeds and Weekly Newsletters Fueled by Company’s ACCELERATE Marketing Solutions Services

 

HAMILTON, N.J. — (BUSINESS WIRE)–Dodge Data & Analytics and The Blue Book today announced plans to publish a suite of four microsites, each with a unique editorial focus designed to serve different sectors of the construction industry.

COLUMN, the first of the four microsites that launched today, is a new content outlet that celebrates the art and science of smarter building. COLUMN is an editorial destination covering the issues that matter most to building industry professionals, including technology, design, sustainability, business and finance, health, safety and wellness.

 

The microsites will serve as a centralized editorial space for the construction industry’s most important and timely resources such as research reports, webinars, whitepapers, podcasts, executive Q&As, analysis on current events, legislation and more. Additional microsites will be announced in the coming weeks.

 

“COLUMN’s content is built on the world-class data, analytics and industry insights of Dodge Data & Analytics and The Blue Book,” said Dave Colford, Chief Revenue Officer. “With these microsites, we hope to serve a diverse audience of architects, contractors, developers, engineers, and other professionals who are united in the desire for a more efficient, economical, healthy, sustainable and just way of building.”

 

COLUMN’s first sponsor, Big Ass Fans, is an American company that manufactures fans and comfort solutions for industrial, agricultural, commercial, and residential use.

 

The second sponsor, Nucor Corporation, is a manufacturer of steel and steel products, with operating facilities in the United States, Canada and Mexico. Their Construction Solutions team is a nationwide team that is a proactive resource, leveraging Nucor’s unique position in the supply chain and vast experience to assist teams at every stage of the design and construction process. Reach out today for assistance on your project challenges.

 

COLUMN’s third initial sponsor, Andersen Windows, is an international window and door manufacturing enterprise based in Bayport, MN.

 

And the fourth sponsor, Hexagon PPM, serves the entire building ecosystem – spanning the entire building lifecycle – empowering customers to design, plan, build and operate buildings more profitably, and sustainably than at any time in history. With 50+ years of experience in delivering innovative software, Hexagon solutions transform disorganized and disparate data into intelligent, actionable information. This enables smarter design, construction, and operation of projects across the asset lifecycle.

 

To stay up to date on all things construction, and for the latest COLUMN posts and content, follow @DodgeData on Twitter and on LinkedIn.

 

About Dodge Data & Analytics

Dodge Data & Analytics is North America’s leading provider of commercial construction project data, market forecasting & analytics services and workflow integration solutions for the construction industry. Building product manufacturers, architects, engineers, contractors, and service providers leverage Dodge to identify and pursue unseen growth opportunities that help them grow their business. On a local, regional or national level, Dodge empowers its customers to better understand their markets, uncover key relationships, seize growth opportunities, and pursue specific sales opportunities with success. The company’s construction project information is the most comprehensive and verified in the industry.

 

As of April 15th, Dodge Data & Analytics and The Blue Book — the largest, most active network in the U.S. commercial construction industry — combined their businesses in a merger. The Blue Book Network delivers three unparalleled databases of companies, projects, and people.

 

Dodge and The Blue Book offer 10+ billion data elements and 14+ million project and document searches. Together, they provide a unified approach for new business generation, business planning, research, and marketing services users can leverage to find the best partners to complete projects and to engage with customers and prospects to promote projects, products, and services. To learn more, visit: construction.com and thebluebook.com.

Contacts

Eric Becker

104 West Partners

eric.becker@104west.com

Categories
Business

AM Best revises outlooks to negative for Armed Forces Insurance Exchange

OLDWICK, N.J. — (BUSINESS WIRE) — #insurance—AM Best has revised the outlooks to negative from stable and affirmed the Financial Strength Rating of B+ (Good) and the Long-Term Issuer Credit Rating of “bbb-” (Good) of Armed Forces Insurance Exchange (AFIE) (Leavenworth, KS).

The ratings reflect AFIE’s balance sheet strength, which AM Best assesses as strong, as well as its marginal operating performance, limited business profile and marginal enterprise risk management (ERM).

 

 

The negative outlooks reflect AM Best’s concerns over the company’s operating performance given its prolonged inability to generate favorable operating results, which has led to surplus erosion and a decline in overall risk-adjusted capitalization. Adverse operating results have persisted for five consecutive years and resulted in the exchange’s five-year average combined and operating ratios reaching levels that compare unfavorably with AM Best’s personal property composite. The adverse operating results were due to frequent and severe weather-related events, particularly in 2020 with 13 named hurricanes making landfall in the United States. As a result, the company’s policyholder surplus has fallen nearly 38% during the latest five-year period. Management has implemented numerous actions to stabilize performance and increase capitalization. These actions include aggressive rate increases, property inspections, and adding affinity partnerships. However, the benefit from these actions remains to be seen.

 

 

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments.

 

 

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

 

Copyright © 2021 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

David Braisted
Financial Analyst
+1 908 439 2200, ext. 5120
david.braisted@ambest.com

Christopher Sharkey

Manager, Public Relations
+1 908 439 2200, ext. 5159

christopher.sharkey@ambest.com

Joseph Burtone
Director
+1 908 439 2200, ext. 5125
joseph.burtone@ambest.com

Jim Peavy
Director, Communications
+1 908 439 2200, ext. 5644
james.peavy@ambest.com

Categories
Local News Science

Bristol Myers Squibb shares research supporting correlation between New York Heart Association functional class (NYHA class) and mortality in obstructive hypertrophic cardiomyopathy

Data presented at Heart Failure Society of America Annual Scientific Meeting show worse NYHA class correlates with increased mortality risk among patients with obstructive hypertrophic cardiomyopathy (obstructive HCM)

 

PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #Cardio—Bristol Myers Squibb (NYSE: BMY) today announced findings from a global real-world evidence study that the risk of mortality increases with worse New York Heart Association functional class (NYHA class) for patients with obstructive hypertrophic cardiomyopathy (obstructive HCM). While other studies have documented this association in HCM, this study represents one of the largest, multi-centered studies that specifically focuses on the obstructive HCM patient population.

“These data demonstrate the importance of assessing NYHA functional class in obstructive HCM patients,” said Neal Lakdawala, MD, cardiovascular medicine specialist at Brigham and Women’s Hospital and lead author on the study. “We should determine the impact of therapies for obstructive HCM on patients’ overall prognosis.”

 

 

Over a median follow-up of 3.9 years, the data show a 5% mortality rate in obstructive HCM patients initially classified as NYHA class I, 9% in class II, and 13% in class III/IV. Risks of all-cause mortality and the composite outcome of death or heart transplant increased with worse NYHA class at baseline (p<0.001). The study was conducted in partnership with the Sarcomeric Human Cardiomyopathy Registry (SHaRe) and presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting taking place from September 10 to 13, 2021.

 

 

The full data presentation will be available starting September 10, 2021, 6:15 p.m. – 7:15 p.m. MT on the HFSA website for registered attendees.

 

 

“As approximately half a million people are affected by obstructive HCM worldwide, these data on the association between mortality and NYHA class in obstructive HCM patients are critical globally,” said Mitch Higashi, vice president of U.S. Health Economics and Outcomes Research, Bristol Myers Squibb. “The insight provided by these real-world data in identifying at-risk patients supports improved patient outcomes as well as healthcare efficiencies overall.”

 

 

About the Study

The study analyzed 2,495 obstructive HCM patients with a mean age of 47.6 years at diagnosis, 42% of whom were female. Patient characteristics varied across NYHA class. The Sarcomeric Human Cardiomyopathy Registry (SHaRe) enrolled patients from 10 HCM specialty centers worldwide. The study used data through March 2019, analyzing patients ≥18 years old with obstructive HCM (left ventricular outflow tract (LVOT) peak gradient >30 mmHg or septal reduction therapy) and documentation of NYHA class. Patients were followed from the date of index NYHA class assessment (first documentation of NYHA class I, II, III or IV) to last SHaRe visit or death. The risks of all-cause mortality and a composite endpoint of death and heart transplant were compared across index NYHA classes using log-rank tests.

 

 

About Obstructive Hypertrophic Cardiomyopathy

Obstructive hypertrophic cardiomyopathy (obstructive HCM), the most common type of HCM, is a chronic, progressive disease in which the heart muscle becomes abnormally enlarged or thick causing the left ventricular outflow tract (LVOT) where blood leaves the heart to become obstructed by the enlarged heart muscle. As a result, obstructive HCM can lead to debilitating symptoms for patients and has also been associated with increased risks of atrial fibrillation, stroke, heart failure and sudden cardiac death.

The most frequent cause of obstructive HCM is mutations in the heart muscle proteins of the sarcomere and as many as 50% of patients have a hereditary predisposition to the disease. Obstructive HCM is estimated to affect 400,000-600,000 people worldwide, however many patients remain undiagnosed and/or asymptomatic.

 

 

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

 

 

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that mavacamten may not receive regulatory approval for the indication described in this release in the currently anticipated timeline or at all, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether such product candidate for such indication described in this release will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2020, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

corporatefinancial-news

Contacts

Bristol Myers Squibb

Media Inquiries:
Media@bms.com

Susan Francis

Susan.Francis@bms.com
609-529-0676

Investors:
Tim Power

Timothy.Power@bms.com
609-252-7509

Categories
Business

Kin Insurance grows total written premium by 287% year-over-year in second quarter 2021

Increases Pace of Growth While Improving Loss Ratio

 

CHICAGO — (BUSINESS WIRE) — Kin Insurance (“Kin” or the “Company”), a leading direct-to-consumer homeowners insurance technology company that has entered into a definitive business combination agreement with Omnichannel Acquisition Corp. (NYSE: OCA) (“Omnichannel”), today announced select preliminary operating results for the second quarter ended June 30, 2021:


  • Total Written Premium increased to $24.7 million for the second quarter of 2021, nearly four times the $6.4 million of Total Written Premium in the prior-year comparative period. Growth was entirely organic and directly written without the use of independent agents.
  • $22.9 million (93%) of second quarter 2021 Total Written Premium was written through the Kin Interinsurance Network (the “Carrier”), a reciprocal exchange managed by Kin Insurance, Inc.
  • Premium Renewal Rate on the Carrier remained strong at 92% in the second quarter of 2021.
  • Gross Profit from Kin’s Management Operations grew 354% to $6.8 million, compared to $1.5 million in the prior-year comparative period.
  • Operating Loss of ($6.9M) was unchanged compared to the first quarter of 2021.
  • Adjusted Loss Ratio1 on the Carrier for the first half of 2021 was 67%, a 29 point improvement compared to 96% in the prior-year period.
Summary Financials
Results are for Shareholder Interest (Kin Insurance Inc.)

2020

2021
($mm) Q1 Q2 Q3 Q4 Q1 Q2
Total Written Premium

4.8

6.4

5.4

8.5

16.4

24.7

% growth (YoY)

39

%

27

%

126

%

278

%

244

%

287

%
Revenue

1.1

1.5

1.4

2.2

4.4

6.8

% growth (YoY)

170

%

172

%

279

%

357

%

317

%

354

%
% of written premium

22

%

24

%

25

%

26

%

27

%

28

%
Gross Profit

1.1

1.5

1.4

2.2

4.4

6.8

% growth

170

%

172

%

279

%

357

%

317

%

354

%
Operating Expenses

4.1

4.8

5.4

9.1

11.3

13.7

Operating Income

-3.1

-3.3

-4.1

-6.9

-6.9

-6.9

“We performed well in the second quarter, increasing our pace of growth year over year while maintaining our peer-leading unit economics. We also grew Total Written Premium by 50% on a sequential basis, while only growing expenses by 21%,” said Sean Harper, Chief Executive Officer of Kin. “Customers continue to choose Kin because of our efficient pricing, tech-forward product and exceptional customer service.”

 

The Kin Interinsurance Network, the customer-owned reciprocal exchange managed by Kin, had a first half 2021 adjusted loss ratio of 67%, a significant improvement from 96% in the prior-year period. Because the Kin Interinsurance Network is a reciprocal exchange that collects surplus contributions from policyholders, adjusted loss ratio includes the pro-rated portion of the surplus contributions to appropriately compare Kin’s loss ratio to industry peers that do not have this unique feature.

 

“Kin’s technology and direct-to-consumer business model enable us to better execute on sound insurance pricing, underwriting and claims principles,” said Angel Conlin, Chief Insurance Officer of Kin. “We believe our data advantage enables our team of expert actuaries and data scientists to apply our pricing and underwriting more accurately than legacy insurance companies that are more reliant on user and agent input data. This is exciting validation of our continued commitment to actuarially sound pricing, while delighting customers, evidenced in our stable renewal rate.”

 

Business Combination Transaction

On July 19, 2021, Kin entered into a business combination agreement with Omnichannel Acquisition Corp. (NYSE: OCA). The business combination is expected to close in the fourth quarter of 2021. Upon closing, the combined public company will be named Kin Insurance Inc., and is expected to be listed on the NYSE under the new ticker symbol “KI”. Additionally, Kin’s closing on the acquisition of an inactive insurance carrier with licenses in more than 40 states is still expected in the fourth quarter of 2021.

 

About Kin

Kin is the home insurance company for every new normal. By leveraging proprietary technology, Kin delivers fully digital homeowners insurance with an elegant user experience, accurate pricing, and fast, high-quality claims service. Kin offers homeowners, landlord, condo, and mobile home insurance through the Kin Interinsurance Network (KIN), a reciprocal exchange owned by its customers who share in the underwriting profit. Because of its efficient technology and direct-to-consumer model, Kin provides affordable pricing without compromising coverage. To learn more, visit https://www.kin.com.

 

About Omnichannel Acquisition Corp.

Omnichannel Acquisition Corp. (NYSE: OCA) is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. For more information, please visit www.omnichannelcorp.com.

 

Important Information for Investors and Stockholders

This communication relates to a proposed business combination (the “Business Combination”) between Omnichannel Acquisition Corp. (“Omnichannel”) and Kin Insurance, Inc. (“Kin”). In connection with the proposed Business Combination, Omnichannel has filed with the SEC a registration statement on Form S-4 that includes a preliminary proxy statement of Omnichannel in connection with Omnichannel’s solicitation of proxies for the vote by Omnichannel’s stockholders with respect to the proposed Business Combination and a preliminary prospectus of Omnichannel. The final proxy statement/prospectus will be sent to all Omnichannel stockholders, and Omnichannel will also file other documents regarding the proposed Business Combination with the SEC. This communication does not contain all the information that should be considered concerning the proposed Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. Before making any voting or investment decision, investors and security holders are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed Business Combination as they become available because they will contain important information about the proposed transaction.

 

Investors and security holders will be able to obtain free copies of the registration statement, proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by Omnichannel through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by Omnichannel may be obtained free of charge by written request to: Christine Pantoya, Chief Financial Officer, Omnichannel Acquisition Corp., 485 Springfield Avenue #8, Summit, New Jersey 07901.

 

Forward-Looking Statements

This communication includes “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the business of Kin or the combined company after completion of the Business Combination are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward looking statements. These factors include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the transaction agreement and the proposed Business Combination contemplated thereby; (2) the inability to complete the transactions contemplated by the transaction agreement due to the failure to obtain approval of the stockholders of Omnichannel or other conditions to closing in the transaction agreement; (3) the ability to meet the NYSE’s listing standards following the consummation of the transactions contemplated by the transaction agreement; (4) the risk that the proposed transaction disrupts current plans and operations of Kin as a result of the announcement and consummation of the transactions described herein; (5) the ability to recognize the anticipated benefits of the proposed Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (6) costs related to the proposed Business Combination; (7) changes in applicable laws or regulations; and (8) the possibility that Kin may be adversely affected by other economic, business, and/or competitive factors. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Omnichannel’s Annual Report on Form 10-K, and other documents filed by Omnichannel from time to time with the SEC and the registration statement on Form S-4 and proxy statement/prospectus discussed above. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Omnichannel and Kin assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.

Any financial and capitalization information or projections in this communication are forward-looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies, many of which are beyond Omnichannel’s and Kin’s control. While such information and projections are necessarily speculative, Omnichannel and Kin believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection extends from the date of preparation. The assumptions and estimates underlying the projected results are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the projections. The inclusion of financial information or projections in this communication should not be regarded as an indication that Omnichannel or Kin, or their respective representatives and advisors, considered or consider the information or projections to be a reliable prediction of future events.

 

Participants in the Solicitation

Omnichannel, Kin and their respective directors and executive officers may be deemed participants in the solicitation of proxies of Omnichannel stockholders with respect to the proposed Business Combination. Omnichannel stockholders and other interested persons may obtain, without charge, more detailed information regarding the directors and executive officers of Omnichannel Acquisition Corp. and their ownership of Omnichannel’s securities in Omnichannel’s final prospectus relating to its initial public offering, which was filed with the SEC on November 23, 2020 and is available free of charge at the SEC’s website at www.sec.gov, or by written request to: Christine Pantoya, Chief Financial Officer, Omnichannel Acquisition Corp., 485 Springfield Avenue #8, Summit, New Jersey 07901.

Additional information regarding the interests of participants in the solicitation of proxies in connection with the proposed transaction will be included in the proxy statement / prospectus that Omnichannel intends to file with the SEC.

 

No Offer or Solicitation

This communication does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of section 10 of the Securities Act, or an exemption therefrom.

1Adjusted Loss ratio, a non-GAAP financial measure, is the ratio of gross losses and allocated loss adjustment expenses of the Carrier, to the gross earned premium of the Carrier and the pro-rated earned surplus contribution made by policyholders.

Contacts

Kin
Investor Relations
investors@kin.com

Media Relations
press@kin.com

Omnichannel
Investor Relations
oacir@icrinc.com

Media Relations
oacpr@icrinc.com

Categories
Business Healthcare

Bayer announces recipients of the second annual Pulmonary Hypertension Accelerated Awards

  • Seven U.S. researchers working to advance pulmonary hypertension (PH) science and patient care awarded a combined one million dollars in grants
  • Application for the 2021 PHAB Awards is now live for eligible researchers to submit their proposals

 

WHIPPANY, N.J. — (BUSINESS WIRE) — Bayer announced the 2020 recipients of the annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a U.S.-based research grant program created to support clinical research in pulmonary hypertension (PH), with a focus on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The seven recipients will receive a combined total of $1 million in grants over a two-year period, making the PHAB Awards one of the largest industry-funded grant programs focused on PAH and CTEPH in the U.S.

“We are seeing how the COVID-19 pandemic has put pulmonary hypertension patients at an increased mortality risk, making it more imperative than ever to support the exploration, discovery and implementation of scientific research that benefits these patients,” said Sameer Bansilal, M.D., M.S., Medical Director, U.S. Medical Affairs at Bayer. “The PHAB Awards in recognizing the dedicated efforts of worthy researchers, underscores Bayer’s commitment to health for all.”

 

The 2020 recipients are:

  • Nicholas Shelburne, M.D., Vanderbilt University Medical Center, to study the effects of exercise on metabolism and right ventricular function in PAH.
  • Mona Alotaibi, M.D., University of California San Diego, to study integrated high throughput non-targeted LCMS metabolomics in CTEPH.
  • Samuel Rayner, M.D., University of Washington Center for Lung Biology, to study proximal pulmonary vascular compliance and inflammation in PAH.
  • Andrea Frump, M.S., Ph.D., Indiana University School of Medicine, to study targeting apelin and ACE2 in PAH-induced RV failure.
  • Hilary DuBrock, M.D., MMSc, Mayo Clinic, to study improving outcomes of PH associated with chronic kidney disease through better understanding of disease mechanisms.
  • Stephen Chan, M.D., Ph.D., University of Pittsburgh, Vascular Medicine Institute, to study utilizing novel 18F-fluoroglutamine PET imaging in patients with PAH.
  • Jason Yuan, M.D., Ph.D., University of California San Diego, to study endothelial biomarkers for treatment of CTEPH.

 

Continuing to build on the success of past PHAB grants in creating new research opportunities, Bayer also announced that the 2021 PHAB Awards application is now live and encourages qualified researchers to apply here. The deadline for applicants is November 1, 2021.

 

“The PHAB Awards would not be possible without the time and commitment of the independent Grants Review Committee, and I’d like to extend my thanks to this team of medical professionals,” said Amit Sharma, U.S. Vice President of Cardiovascular and Renal Medical Affairs at Bayer. “We look forward to carrying this program forward with the 2021 PHAB Awards. I encourage eligible applicants to submit their research proposals for consideration as soon as possible.”

 

The PHAB Awards selection criteria are modeled on standards used by the National Institutes of Health (NIH) system. Many attributes, including merit, significance, innovation and approach, are evaluated. Award recipients must post their research on ClinicalTrials.gov, and are expected to use best efforts to publish or present study outcomes. If research is not conducted, grant monies must be returned.

 

For a complete description of the PHAB Awards, application criteria and terms, visit https://www.phab-awards.com/awards/ or e-mail PHAB.awards@bayer.com.

 

Grants Review Committee

The PHAB Awards recipients were selected by an independent Grants Review Committee, consisting of the following eminent leaders in PH:

  • William Auger, M.D., FCCP, FCPP, Temple University Medical Center, Philadelphia, PA
  • Richard Channick, M.D., UCLA School of Medicine, Los Angeles, CA
  • Robert P. Frantz, M.D., Mayo Clinic, Rochester, MN
  • Anna R. Hemnes, M.D., Vanderbilt University Medical Center, Nashville, TN
  • Tim Lahm, M.D., Indiana University School of Medicine, Indianapolis, IN
  • Peter Leary, M.D., Ph.D., University of Washington, Seattle, WA
  • Stephen C. Mathai, M.D., Johns Hopkins University School of Medicine, Baltimore, MD
  • John J. Ryan, M.D., BCh, BAO, University of Utah, Salt Lake City, UT
  • Traci Stewart, RN, MSN, CHFN, University of Iowa, Iowa City, IA

 

About Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension (PAH, WHO Group 1) is defined by elevated pressure in the arteries going from the right side of the heart to the lungs. Typical symptoms of PAH include shortness of breath on exertion, fatigue, weakness, chest pain and syncope. PAH is caused by abnormalities in the walls of the pulmonary arteries.1,2

 

About Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Chronic Thromboembolic Pulmonary Hypertension (CTEPH, WHO Group 4) is a progressive type of pulmonary hypertension, in which it is believed that thromboembolic occlusion (organized blood clots) of pulmonary vessels gradually lead to an increased blood pressure in the pulmonary arteries, resulting in an overload of the right heart.3,4 CTEPH may evolve after prior episodes of acute pulmonary embolism, but the pathogenesis is not yet completely understood. The standard and potentially curative treatment for CTEPH is pulmonary thromboendarterectomy (PTE), a surgical procedure in which the blood vessels of the lungs are cleared of clot and scar material.5,6 However, a considerable number of patients with CTEPH (20%-40%) are not operable and in up to 35% of patients, the disease persists or reoccurs after PTE.7

 

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

Our online press service is just a click away: www.bayer.us/en/newsroom
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: https://twitter.com/Bayerus

BAYER and the Bayer Cross are registered trademarks of Bayer.

 

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

References:

1 Galie et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart. 2016;37:67–119.

2American Lung Association. Pulmonary Hypertension. Accessed November 22, 2017. http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/pulmonary-hypertension.

3 Piazza G and Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2011; 364: 351-360.

4 Simonneau G et al. Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology. 2013; 62(25):

5 D’Armini M. Diagnostic advances and opportunities in chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2015; 24: 253–262.

6 Kim et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2013; 62: D92-9.

7 Mathai et al. Quality of life in patients with chronic thromboembolic pulmonary hypertension. Eur Respir J. 2016 Aug; 48(2): 526–537.

Contacts

Media Contact:
Patti Fernandez, Tel. +1 845.300.4091

E-Mail: patricia.fernandez.ext@bayer.com

Categories
Local News Science

UroGen Pharma to present at the H.C. Wainwright 23rd Annual Global Investment Conference

PRINCETON, N.J. — (BUSINESS WIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on-demand via the conference portal and through the Investors section of UroGen’s website, www.urogen.com, beginning at 7:00 a.m. Eastern Time on Monday, September 13, 2021. A replay of the webcast will be available on the website for approximately 30 days.

 

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

Contacts

INVESTOR CONTACTS:
Lee Roth

lroth@burnsmc.com
212-213-0006

Categories
Business

Summit Growth Partners gains momentum with addition of WealthPlan Advantage

Summit makes minority investment, offers long-term strategic support to growing NJ firm

PARSIPPANY, N.J. — (BUSINESS WIRE) — Summit Financial Holdings (“Summit”), a financial services firm and premier destination for independent and breakaway advisors, welcomes WealthPlan Advantage, a 20-year old firm providing investment advisory services focused on holistic wealth management solutions, as the newest member of Summit Growth Partners, a growing network of affiliated, independent advisors.

Located in Morristown, New Jersey, WealthPlan Advantage has received a non-controlling, minority stake investment from Summit Growth Partners. The firm specializes in holistic planning and wealth management service to individuals, families, company executives and business owners. According to Greg Nardolillo, the firm’s founder, “WealthPlan Advantage sought a partner that would help enhance their offering without sacrificing their independence.” As an affiliated member of Summit Growth Partners, WealthPlan Advantage will also adopt SummitVantageTM, an all-inclusive platform of fully integrated industry-leading services, thought leaders, and innovative technology that makes delivering elevated advice nearly frictionless.

 

“Our partnership with Summit lets us tap into a trove of in-house expertise, technology and support that is truly rare to find in one place from a growth partner,” Nardolillo said. “The team at Summit is giving us the tools to grow into our strengths and meet the complex financial needs of the households and businesses we serve.”

 

Nardolillo cites the recent success of Summit Growth Partners in attracting new firms, such as Vardhan Wealth Management and Kandor Global, as well as the existing robust Summit Financial community of advisors.

 

“We’re proud to have cultivated a real community of advisors eager to collaborate and share their wins,” said Stan Gregor, CEO of Summit. “Greg and his team are an invaluable addition to Summit Growth Partners, and we can’t wait to help them thrive and evolve in the years to come.”

 

About Summit Financial Holdings

Summit Financial Holdings, LLC’s affiliated firms include, but are not limited to, Summit Financial, LLC, Summit Risk Management, LLC, Summit Advisory Services, LLC, Summit Services IT, LLC, and Summit Growth Partners, LLC. As an independent financial services firm for almost 40 years through its predecessor, Summit and its affiliates are proud to continue their legacy of guiding clients toward financial success by aligning extensive experience with a forward-thinking philosophy, adapting to industry changes for the sake of best serving our clients now and well into the future. Summit Financial, LLC, is an SEC registered investment advisor established November 2018, and is the successor firm to Summit Equities, Inc. (registered with the SEC in 1991) and Summit Financial Resources, Inc. (registered with the SEC in 1983) for all of their investment advisory and financial planning business. With customized, holistic and hands-on advice, we turn life’s aspirations into success stories. Our financial advice focuses on individual needs and values, not industry norms. To learn more about our firms, please visit our website at www.SummitFinancial.com.

 

Investment advisory and financial planning services offered through Summit Financial, LLC, a SEC Registered Investment Adviser, doing business as WealthPlan Advantage (191 Washington St, Morristown, NJ 07960, (973) 867-1835)

Contacts

Media Contact
Ann Marie Gorden

Gregory FCA for Summit Financial

Summit@GregoryFCA.com
267-249-7765

Categories
Business Sports & Gaming

New York Jets announce a multi-year partnership with Fubo Sportsbook

First NFL team partnership for forthcoming Fubo Sportsbook includes new Fubo Sportsbook Lounge at MetLife Stadium for Jets games

 

FLORHAM PARK, N.J. & CHICAGO — (BUSINESS WIRE) — The New York Jets today announced a multi-year partnership with Fubo Sportsbook, the comprehensive sports entertainment and wagering experience expected to launch in the fourth quarter 2021 (subject to all applicable regulatory approvals), to become an Official Sports Betting partner of the club. This agreement marks Fubo Sportsbook’s first sponsorship of a professional sports team. The partnership centers around the creation of the Fubo Sportsbook Lounge at MetLife Stadium for Jets home games, set to debut during the 2021-22 NFL season, and will be the first authorized, mobile sports betting lounge in the stadium. In addition, Fubo Sportsbook will become the presenting partner of the Jets Mobile App and is the team’s first legal sports betting (LSB) partner to leverage the Jets’ new advertising data partnership with Sportradar.

“This partnership with Fubo Sportsbook is another major step for the New York Jets in our journey to prioritize engagement with our fan base, including the enhancement of their overall stadium experience on game day,” said Jeff Fernandez, Jets Vice President, Business Development + Ventures. “With Fubo Sportsbook, Jets fans will be treated to their innovative mobile viewing and wagering platform, which will be brought to life at the dynamic new Fubo Sportsbook Lounge.”

 

At approximately 7,000 sq. ft., the Fubo Sportsbook Lounge will be open to the public for guests 21 and over and will offer Jets fans the opportunity to enjoy the look and feel of a casino-style sportsbook with betting odds integration, as well as incentives and special bonus offers provided by Fubo Sportsbook. Additionally, fans will be able to watch every game from around the NFL in the Lounge and conduct live mobile wagering via the Fubo Sportsbook app all while enjoying an incredible view of the Jets action on the field from the Lounge’s outdoor patio.

 

“The New York Jets is a leading sports organization with a strong base of enthusiastic and loyal fans and we strongly believe in the future success of the team,” said Scott Butera, President of Fubo Gaming. “We are excited to be their partner in offering this community a truly unique sports betting and entertainment experience. The Fubo Sportsbook is designed to meet the increased demand for interactivity by integrating real-time sports streaming with personalized wagering experiences. The Fubo Sportsbook will also have the ability to leverage first-party data to understand viewing preferences and provide relevant bet recommendations.”

 

Jets Mobile App users will receive access to special Fubo Sportsbook offers as well as game day incentives tied to the Lounge. Fubo Sportsbook customers will also be rewarded with access to unique hospitality including VIP pregame sideline experiences. In addition, Fubo Sportsbook intends to utilize the new programmatic ad network created for the Jets utilizing Sportradar’s programmatic activation platform.

 

ABOUT NEW YORK JETS

The New York Jets were founded in 1959 as the New York Titans, an original member of the American Football League (AFL). The Jets won Super Bowl III, defeating the NFL’s Baltimore Colts in 1969. In 1970, the franchise joined the National Football League in the historic AFL–NFL merger that set the foundation for today’s league. As part of a commitment to its fan base through innovation and experiences, the team has created initiatives such as, its trailblazing Jets Rewards program, a state-of-the-art mobile app, and Jets 360 Productions, a comprehensive content platform that gives fans greater access to the team across all digital and social platforms. The organization takes great pride in a long-standing, year-round commitment to their community. These programs are funded by the New York Jets Foundation and look to positively influence the lives of young men and women in the tri-state area, particularly in disadvantaged communities. The organization supports the efforts of the Lupus Research Alliance, youth football and numerous established charitable organizations and causes sponsored by the NFL. The New York Jets play in MetLife Stadium, which opened in 2010, and are headquartered at the Atlantic Health Jets Training Center in Florham Park, New Jersey.

 

ABOUT FUBO GAMING

Fubo Gaming Inc., is a Chicago-based subsidiary of live TV streaming platform fuboTV Inc. (NYSE: FUBO) that is dedicated to delivering a unique, hyper-personalized sports entertainment and wagering experience. Launched in 2021, Fubo Gaming brings together fuboTV’s leading sports-first live TV streaming platform with the soon-to-be-launched Fubo Sportsbook to create an omniscreen ecosystem in which the wagering app automatically syncs with users’ interests and viewing. Fubo Sportsbook is expected to launch in Q4 2021, subject to obtaining requisite regulatory approvals. In addition to its licenses and market access agreements in Arizona via Ak-Chin Indian Community and Iowa via Casino Queen, Fubo Gaming has also obtained market access agreements in Pennsylvania via The Cordish Companies as well as Indiana and New Jersey via Caesars Entertainment Inc. For more information, visit fubosportsbook.com.

Contacts

Meghan Gilmore, New York Jets

mgilmore@jets.nfl.com

Deliah Mathieu, Fubo Gaming

dmathieu@fubo.tv

Lexi Panepinto, Fubo Gaming

lpanepinto@ctpboston.com

Categories
Science Technology

Tevogen Bio reaches major milestone in commercial manufacturing readiness by completing the technology transfer of its investigational COVID-19 T cell therapy

METUCHEN, N.J. — (BUSINESS WIRE) — #COVID19–Tevogen Bio announced the completion of technology transfer of its investigational COVID-19 therapy TVGN-489 to BioCentriq, Tevogen’s clinical manufacturing partner, representing a major milestone in achieving commercial manufacturing readiness. TVGN-489 consists of Allogeneic COVID-19 Specific Cytotoxic CD8+ T Lymphocytes (CTLs), which are specifically designed for the treatment of high-risk patients who are at-risk of breakthrough infections and progressing to severe COVID-19.

“The troubling emergence of breakthrough cases and new variants highlights that the fight against this virus is not over,” said Ryan Saadi, MD, MPH, and CEO of Tevogen Bio. “We have spent significant resources and time identifying the TVGN-489 targets across the viral genome which are less likely to mutate under evolutionary pressure. With the completion of technology transfer and the initiation of the clinical trial, Tevogen is one step closer to realizing the potential of this breakthrough innovation becoming a vital tool in the fight against COVID-19.”

 

BioCentriq’s experience in cell and gene therapy manufacturing will help expedite the process of making Tevogen’s disruptive innovations accessible to patients. “The milestone represents the commitment of both entities to expedite patient access to Tevogen’s proprietary investigational SARS-CoV-2 specific T cell therapy. The team at BioCentriq is uniquely equipped to help us meet our goal of delivering personalized immunotherapies to large patient populations for the first time ever,” Saadi stated.

 

The POC trial of TVGN-489 is now underway to evaluate the safety and optimal dosage of the therapy for the treatment of high-risk COVID-19 patients. TVGN-489 has demonstrated strong antiviral activity against SARS-CoV-2 in preclinical studies.

 

About TVGN-489

TVGN-489 is highly purified SARS-CoV-2 specific cytotoxic CD8+ T lymphocytes programmed to detect targets spread across the entire viral genome. These targeted CTLs are expected to recognize and kill off virus infected cells, allowing the body to replace them with healthy uninfected cells.

 

Dr. Neal Flomenberg, Chairman of Tevogen’s Scientific Advisory Board, said, “CTLs are the tools normally used by our bodies to eliminate viral infections. Current COVID-19 treatments attempt to slow the virus until our own CTLs can develop in adequate numbers to eliminate the infection. In contrast, TVGN-489 provides substantial numbers of highly enriched, highly potent SARS-CoV-2 specific CTLs directly to the patients. It is because we are using nature’s own tools that we are optimistic that this approach will prove both safe and effective.”

 

About Tevogen Bio

Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. In collaboration with key strategic partners, the company moved its lead product from discovery to clinical phase within 12 months of inception, shaving years off the industry’s standard for drug development timelines.

 

Tevogen leadership believes that affordable personalized immunotherapies are the next frontier of medicine and disruptive business models are required to sustain medical innovation in the post pandemic world. The company’s breakthrough technology overcomes traditional barriers to the broad application of targeted T cell therapies through revolutionary advances in speed to patient and product purity. Tevogen’s focus on organizational and manufacturing efficiency is core to its highly successful biopharma business model and goal to make personalized immunotherapies accessible to the masses for the first time. Tevogen Bio’s research pipeline includes targeted CD8+ T Lymphocyte therapeutics for the treatment of common cancers (NSCLC, Cervical Cancer) and difficult to eradicate serious viral infections (Hepatitis B). www.tevogen.com

 

About BioCentriq

BioCentriq™ is a full service CDMO for cell and gene therapy process development and clinical manufacturing with a GMP clinical manufacturing facility in Newark, NJ, and a pilot plant in South Brunswick, NJ. The company develops and manufactures autologous and allogeneic cell therapies, gene therapies, and specializes in viral vectors, cell and viral banking, and upstream and downstream processing. BioCentriq also manufactures immunotherapies, including monoclonal antibodies and proteins, vaccines, and offers workforce development programs. www.biocentriq.com

 

Forward Looking Statements

This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc.’s (the “Company”) development and patient access of its innovations in infectious diseases and oncology. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors not under the company’s control which may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations implied by these forward-looking statements. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These factors include results of current or pending clinical trials, risks associated with intellectual property protection, financial projections, sales, pricing and actions by the FDA/EMA. The Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and make no representations or warranties in connection herewith or with respect to any omissions herefrom.

Contacts

Media:

Carla Angel

Carla.angel@tevogen.com

Amy Lamperti

Amy.lamperti@biocentriq.com